A case report of de novo immune thrombocytopenic purpura (ITP) following COVID-19-mRNA vaccination: 2-year clinical follow up.

Published: 29 February 2024| Version 1 | DOI: 10.17632/wvdxt4r9yw.1


After vaccination with mRNA vaccines, several cases of autoimmune diseases have been reported. We presented a case report of an adult male patient, without any previous report of thrombocytopenia or other hematologic disorders, who developed a chronic paucisymptomatic or mild ITP secondary to SARS-CoV-2 m-RNA vaccine. The patient received the first and second doses of mRNA BNT162b2 vaccine (June/2021), the first booster dose of mRNA-1273 (November/2021), and the second booster dose of mRNA BNT162b2 (June/2022). Thrombocytopenia was documented after each vaccination. After corticoids therapy was implemented, the patient improved. However, cycling thrombocytopenia was documented until August/2023 (mean: 103 x109 platelets/L).



Universidad de Santander


Case Report, Immune Thrombocytopenic Purpura, COVID-19 Vaccine